{"id":5426,"date":"2025-12-02T17:41:00","date_gmt":"2025-12-02T14:41:00","guid":{"rendered":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2026\/01\/19\/25-kasim-2025-tarihli-sut-degisikligi-hk\/"},"modified":"2026-01-19T11:12:32","modified_gmt":"2026-01-19T08:12:32","slug":"25-kasim-2025-tarihli-sut-degisikligi-hk","status":"publish","type":"post","link":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/","title":{"rendered":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK."},"content":{"rendered":"<div style=\"padding-bottom: 100px; margin: auto; width: 90%; display: flex; justify-content: center; flex-direction: column;\">\n<p style=\"margin-left: 18pt; text-align: center;\"><b><span style=\"font-family:&quot;Times New Roman&quot;,serif\">25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130<br \/>\n   <o:p><\/o:p><\/span><\/b><\/p>\n<p class=\"MsoNormal\" align=\"center\" style=\"margin-left:18.0pt;text-align:center\"><b><span style=\"font-family:&quot;Times New Roman&quot;,serif\">B\u0130LG\u0130 NOTU<br \/>\n   <o:p><\/o:p><\/span><\/b><\/p>\n<p class=\"MsoNormal\" style=\"text-align:justify\"><b><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;<\/span><\/b><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">\u201c4.2.1.C-Biyolojik ajanlar\u201d ba\u015fl\u0131kl\u0131 maddesine; \u201c<span style=\"color:#00B050\">(5) Tan\u0131 de\u011fi\u015fikli\u011finin olu\u015fmas\u0131 halinde yeni tan\u0131da idame kriterleri ge\u00e7erlidir.<\/span>\u201d f\u0131kras\u0131 eklenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family:\n&quot;Times New Roman&quot;,serif\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">\u201c4.2.1.C-5 -Tosilizumab\u201d etkin maddesiyle <b>(ACTEMRA)<\/b> ilgili olarak Dev h\u00fccreli arteriti tan\u0131s\u0131nda;<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 54pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">-\u201c<span style=\"color:#00B050\">Y\u00fcksek doz kortikosteroidle birlikte Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131ndan onayl\u0131 olmas\u0131 halinde methotreksat, leflunomid, azatioprinin herhangi birinin 3 ay s\u00fcre ile kullan\u0131lm\u0131\u015f olmas\u0131na ra\u011fmen yan\u0131t al\u0131namamas\u0131 durumunda.<\/span>\u201d maddesi eklenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 54pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">-Rapor ve re\u00e7ete d\u00fczenleyebilen hekimler aras\u0131ndan, \u201cAlerji uzman hekimleri\u201d \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">4.2.1.C-6 maddesinde, upadasitinib etkin maddesinin <b>(RINVOQ)<\/b> \u201cUpadasitinibin Dev H\u00fccreli Arteriti (DHA) hastal\u0131\u011f\u0131nda\u201d kullan\u0131m\u0131nda geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">4.2.1.C-9- Sekukinumab <b>(VERXANT)<\/b> maddesinde, \u201cAktif orta il\u0103 \u015fiddetli hidradenitis s\u00fcp\u00fcratival\u0131 (akne inversa) eri\u015fkin hastalarda\u201d kullan\u0131m\u0131na y\u00f6nelik geri \u00f6deme ko\u015fullar\u0131 belirlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u201cvortioksetin\u201d etkin maddeli ila\u00e7lar <b>(FONKSERA, SORDENA)<\/b>; \u201c<\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;color:#EE0000\">yaln\u0131zca orta veya a\u011f\u0131r depresif bozukluk tedavisinde<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u201d kar\u015f\u0131lan\u0131rken, yap\u0131lan de\u011fi\u015fiklik ile geri \u00f6deme ko\u015fulu \u201c<\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\ncolor:#00B050\">major depresif epizotlar\u0131n tedavisinde<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u201d \u015feklinde d\u00fczenlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">4.2.2 maddesinden \u201c<\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\ncolor:#EE0000\">Brekspiprazol etkin maddeli ila\u00e7lar <\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(REXULTI)<\/span><\/b><span style=\"font-family:&quot;Times New Roman&quot;,serif;color:#EE0000\"> maj\u00f6r depresif bozukluk (MDD) endikasyonunda \u00f6denmez.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u201d \u0130fadesi kald\u0131r\u0131lm\u0131\u015ft\u0131r.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">DMAH\u2019lar\u0131n raporsuz olarak re\u00e7ete edilme ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, ba\u015flang\u0131\u00e7 rapor s\u00fcresi 3 aydan 6 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. 1 y\u0131l rapor s\u00fcreli devam tedavisi ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, 1 y\u0131ldan uzun s\u00fcreli kullan\u0131ma ili\u015fkin olan d\u00fczenleme 6 aya indirilmi\u015ftir. Gebelikte geri \u00f6denme ko\u015fuluna ili\u015fkin rapor s\u00fcresi 9 aydan 10 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. Raporsuz acil ve yatan hastalarda t\u00fcm hekimlerce re\u00e7ete edilmesi halinde \u00f6denmeye devam edecektir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">Abirateron etkin maddesinin <\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(ABIRATEX)<\/span><\/b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"> geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u0130ksazomib<b>(NINLARO)<\/b>, karfilzomib<b>(KYPROLIS)<\/b>, daratumumab<b>(DARZALEX)<\/b><\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\nmso-fareast-font-family:Calibri;color:#00B050\">, <a name=\"_Hlk215483748\">isatuksimab<\/a><\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(SARCLISA)<\/span><\/b><span style=\"font-family:&quot;Times New Roman&quot;,serif;\nmso-fareast-font-family:Calibri;color:#00B050\">, elranatamab<\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(ELREXFIO)<\/span><\/b><span style=\"font-family:&quot;Times New Roman&quot;,serif;\nmso-fareast-font-family:Calibri;color:#00B050\">, selineksor<\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(NEXPOVIO)<\/span><\/b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"> <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">ve pomalidomid<b>(IMNOVID)<\/b> etken maddeli ila\u00e7lar\u0131n \u00f6zel h\u00fck\u00fcmleri d\u0131\u015f\u0131nda birbirleri ile kombine olarak kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:Calibri;\ncolor:#00B050\">Daratumumab direnci olan hastalarda isatuksimab\u0131n, isatuksimab direnci olan hastalarda daratumumab\u0131n kullan\u0131lmas\u0131 halinde bedelleri Kurumca <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:Calibri;\ncolor:#00B050\">\u201cisatuksimab\u201d, \u201celranatamab\u201d,<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"> <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:\nCalibri;color:#00B050\">\u201cselineksor\u201d <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">ve<\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:Calibri;\ncolor:#00B050\"> \u201cfedratinib\u201d<\/span><b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">(INREBIC) <\/span><\/b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">etkin maddelerinin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-bidi-font-weight:bold\">\u0130ki ya\u015f\u0131na kadar inek s\u00fct\u00fc ve\/veya \u00e7oklu g\u0131da protein alerjisi olan bebeklerde kullan\u0131lan t\u0131bbi mamalar i\u00e7in rapor d\u00fczenleyebilecek hekimlere <span style=\"color:#00B050\">\u00e7ocuk alerji <\/span>uzman hekimleri eklenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">Dan\u0131\u015ftay 10. Dairesinin 30.10.2024 tarih ve 2023\/4913 esas say\u0131l\u0131 karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; Mepolizumab<b>(NUCALA)<\/b> ve benralizumab<b>(FASENRA)<\/b> etkin maddelerinin ast\u0131m tan\u0131s\u0131nda kullan\u0131lmas\u0131na ili\u015fkin rapor ve re\u00e7ete d\u00fczenleyebilecek hekimler aras\u0131na <span style=\"color:#00B050\">alerji <\/span>uzman hekimleri eklenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">\u201cKombine koag\u00fclasyon fakt\u00f6r\u00fc\/protrombinkompleksi konsantreleri\u201d geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">Bosentan etkin maddesini 32 mg dozunda i\u00e7eren ila\u00e7lar\u0131n pulmoner arteriyel hipertansiyonda ve Dijital \u00fclseri olan sistemik skleroz hastalar\u0131nda kullan\u0131m\u0131na ili\u015fkin geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir.<\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">Empagliflozin ve linagliptin etkin maddelerini kombine \u015fekilde i\u00e7eren ila\u00e7lar\u0131n <b>(GLYXAMBI)<\/b> <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015f olup; <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\nmso-fareast-font-family:&quot;\u30d2\u30e9\u30ae\u30ce\u660e\u671d Pro W3&quot;;color:#00B050;mso-bidi-font-weight:\nbold\">Linagliptin ve empagliflozin kombinasyonunun, di\u011fer DPP-4 antagonistleri, SGLT2 inhibit\u00f6rleri ve GLP-1 analoglar\u0131 ile birlikte kullan\u0131lmas\u0131 halinde bedelleri Kurumca <\/span><b><span style=\"font-family:&quot;Times New Roman&quot;,serif;mso-fareast-font-family:&quot;\u30d2\u30e9\u30ae\u30ce\u660e\u671d Pro W3&quot;;\ncolor:#00B050\">kar\u015f\u0131lanmayaca\u011f\u0131 <\/span><\/b><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">belirtilmi\u015ftir.<\/span><\/li>\n<\/ul>\n<p style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\"><br \/><\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u0130\u00e7 referans <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif\">fiyatland\u0131rma uygulamas\u0131ndaki, grubun en ucuz ila\u00e7 bedelinin %10 fazlas\u0131na kadar\u0131 dikkate al\u0131nmas\u0131 hususundaki oran, %6 olarak g\u00fcncellenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar listesine <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\ncolor:#00B050\">\u0130satuksimab <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">ve <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif;\ncolor:#00B050\">Sekukinumab <\/span><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">etkin maddeleri eklenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">Siklopiroks olamin \u015fampuan formlar\u0131 <b>(LOPROX \u015eAMPUAN)<\/b> i\u00e7in Ek-4\/E\u2019de yer alan re\u00e7ete edilme ko\u015fulu, aile hekimlerinin de re\u00e7ete edebilece\u011fi \u015fekilde d\u00fczenlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">EK-4\/F Listesinde Paliperidonun 6 ayl\u0131k depo parenteral formlar\u0131 i\u00e7in geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir.<br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<ul>\n<li style=\"margin-left: 18pt; text-align: justify;\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">28.02.2022 tarihli Dan\u0131\u015ftay Karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; EK-4\/F Listesinde <\/span><span style=\"font-family:&quot;Times New Roman&quot;,serif\">solifenasin, tolterodine-L, trospiyum, darifenasin, propiverin, fesoterodin, mirabegron, transdermal oksibutinin ile duloksetin etkin maddeleri i\u00e7in <span style=\"color:#00B050\">rapor \u015fart\u0131 getirilmi\u015f ve rapor d\u00fczenleyebilen hekimlere geriatri uzman hekimi eklenmi\u015ftir.<\/span><br \/>\n   <o:p><\/o:p><\/span><\/li>\n<\/ul>\n<p class=\"MsoListParagraph\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">&nbsp;<\/span><\/p>\n<\/p>\n<p class=\"MsoNormal\" style=\"margin-left:54.0pt\"><span style=\"font-family: &quot;Times New Roman&quot;, serif;\">\u0130\u00e7 referans <\/span><span style=\"font-family:\n&quot;Times New Roman&quot;,serif\">fiyatland\u0131rma ve e\u015fde\u011fer band\u0131 uygulamas\u0131 27.11.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girmi\u015f olup, di\u011fer de\u011fi\u015fiklikler 03.12.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir.<\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin-left:54.0pt\"><span style=\"font-family:\n&quot;Times New Roman&quot;,serif\"><br \/><\/span><\/p>\n<ul>\n<li style=\"margin-left: 54pt;\"><a href=\"https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf\" target=\"_blank\" style=\"background-color: rgb(255, 255, 255);\"><font color=\"#0000ff\"><u><b>https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf<\/b><\/u><\/font><\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 B\u0130LG\u0130 NOTU &nbsp; \u201c4.2.1.C-Biyolojik ajanlar\u201d ba\u015fl\u0131kl\u0131 maddesine; \u201c(5) Tan\u0131 de\u011fi\u015fikli\u011finin olu\u015fmas\u0131 halinde yeni tan\u0131da idame kriterleri ge\u00e7erlidir.\u201d f\u0131kras\u0131 eklenmi\u015ftir. &nbsp; \u201c4.2.1.C-5 -Tosilizumab\u201d etkin maddesiyle (ACTEMRA) ilgili olarak Dev h\u00fccreli arteriti tan\u0131s\u0131nda; &nbsp; -\u201cY\u00fcksek doz kortikosteroidle birlikte Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131ndan onayl\u0131 olmas\u0131 halinde methotreksat, leflunomid, azatioprinin herhangi birinin 3 ay s\u00fcre ile kullan\u0131lm\u0131\u015f olmas\u0131na ra\u011fmen yan\u0131t al\u0131namamas\u0131 durumunda.\u201d maddesi eklenmi\u015ftir. &nbsp; -Rapor ve re\u00e7ete d\u00fczenleyebilen hekimler aras\u0131ndan, \u201cAlerji uzman hekimleri\u201d \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. &nbsp; 4.2.1.C-6 maddesinde, upadasitinib etkin maddesinin (RINVOQ) \u201cUpadasitinibin Dev H\u00fccreli Arteriti (DHA) hastal\u0131\u011f\u0131nda\u201d kullan\u0131m\u0131nda geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; 4.2.1.C-9- Sekukinumab (VERXANT) maddesinde, \u201cAktif orta il\u0103 \u015fiddetli hidradenitis s\u00fcp\u00fcratival\u0131 (akne inversa) eri\u015fkin hastalarda\u201d kullan\u0131m\u0131na y\u00f6nelik geri \u00f6deme ko\u015fullar\u0131 belirlenmi\u015ftir. &nbsp; \u201cvortioksetin\u201d etkin maddeli ila\u00e7lar (FONKSERA, SORDENA); \u201cyaln\u0131zca orta veya a\u011f\u0131r depresif bozukluk tedavisinde\u201d kar\u015f\u0131lan\u0131rken, yap\u0131lan de\u011fi\u015fiklik ile geri \u00f6deme ko\u015fulu \u201cmajor depresif epizotlar\u0131n tedavisinde\u201d \u015feklinde d\u00fczenlenmi\u015ftir. &nbsp; 4.2.2 maddesinden \u201cBrekspiprazol etkin maddeli ila\u00e7lar (REXULTI) maj\u00f6r depresif bozukluk (MDD) endikasyonunda \u00f6denmez.\u201d \u0130fadesi kald\u0131r\u0131lm\u0131\u015ft\u0131r. &nbsp; DMAH\u2019lar\u0131n raporsuz olarak re\u00e7ete edilme ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, ba\u015flang\u0131\u00e7 rapor s\u00fcresi 3 aydan 6 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. 1 y\u0131l rapor s\u00fcreli devam tedavisi ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, 1 y\u0131ldan uzun s\u00fcreli kullan\u0131ma ili\u015fkin olan d\u00fczenleme 6 aya indirilmi\u015ftir. Gebelikte geri \u00f6denme ko\u015fuluna ili\u015fkin rapor s\u00fcresi 9 aydan 10 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. Raporsuz acil ve yatan hastalarda t\u00fcm hekimlerce re\u00e7ete edilmesi halinde \u00f6denmeye devam edecektir. &nbsp; Abirateron etkin maddesinin (ABIRATEX) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; \u0130ksazomib(NINLARO), karfilzomib(KYPROLIS), daratumumab(DARZALEX), isatuksimab(SARCLISA), elranatamab(ELREXFIO), selineksor(NEXPOVIO) ve pomalidomid(IMNOVID) etken maddeli ila\u00e7lar\u0131n \u00f6zel h\u00fck\u00fcmleri d\u0131\u015f\u0131nda birbirleri ile kombine olarak kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Daratumumab direnci olan hastalarda isatuksimab\u0131n, isatuksimab direnci olan hastalarda daratumumab\u0131n kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u201cisatuksimab\u201d, \u201celranatamab\u201d, \u201cselineksor\u201d ve \u201cfedratinib\u201d(INREBIC) etkin maddelerinin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u0130ki ya\u015f\u0131na kadar inek s\u00fct\u00fc ve\/veya \u00e7oklu g\u0131da protein alerjisi olan bebeklerde kullan\u0131lan t\u0131bbi mamalar i\u00e7in rapor d\u00fczenleyebilecek hekimlere \u00e7ocuk alerji uzman hekimleri eklenmi\u015ftir. &nbsp; Dan\u0131\u015ftay 10. Dairesinin 30.10.2024 tarih ve 2023\/4913 esas say\u0131l\u0131 karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; Mepolizumab(NUCALA) ve benralizumab(FASENRA) etkin maddelerinin ast\u0131m tan\u0131s\u0131nda kullan\u0131lmas\u0131na ili\u015fkin rapor ve re\u00e7ete d\u00fczenleyebilecek hekimler aras\u0131na alerji uzman hekimleri eklenmi\u015ftir. &nbsp; \u201cKombine koag\u00fclasyon fakt\u00f6r\u00fc\/protrombinkompleksi konsantreleri\u201d geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Bosentan etkin maddesini 32 mg dozunda i\u00e7eren ila\u00e7lar\u0131n pulmoner arteriyel hipertansiyonda ve Dijital \u00fclseri olan sistemik skleroz hastalar\u0131nda kullan\u0131m\u0131na ili\u015fkin geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Empagliflozin ve linagliptin etkin maddelerini kombine \u015fekilde i\u00e7eren ila\u00e7lar\u0131n (GLYXAMBI) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015f olup; Linagliptin ve empagliflozin kombinasyonunun, di\u011fer DPP-4 antagonistleri, SGLT2 inhibit\u00f6rleri ve GLP-1 analoglar\u0131 ile birlikte kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 belirtilmi\u015ftir. \u0130\u00e7 referans fiyatland\u0131rma uygulamas\u0131ndaki, grubun en ucuz ila\u00e7 bedelinin %10 fazlas\u0131na kadar\u0131 dikkate al\u0131nmas\u0131 hususundaki oran, %6 olarak g\u00fcncellenmi\u015ftir. &nbsp; Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar listesine \u0130satuksimab ve Sekukinumab etkin maddeleri eklenmi\u015ftir. &nbsp; Siklopiroks olamin \u015fampuan formlar\u0131 (LOPROX \u015eAMPUAN) i\u00e7in Ek-4\/E\u2019de yer alan re\u00e7ete edilme ko\u015fulu, aile hekimlerinin de re\u00e7ete edebilece\u011fi \u015fekilde d\u00fczenlenmi\u015ftir. &nbsp; EK-4\/F Listesinde Paliperidonun 6 ayl\u0131k depo parenteral formlar\u0131 i\u00e7in geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; 28.02.2022 tarihli Dan\u0131\u015ftay Karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; EK-4\/F Listesinde solifenasin, tolterodine-L, trospiyum, darifenasin, propiverin, fesoterodin, mirabegron, transdermal oksibutinin ile duloksetin etkin maddeleri i\u00e7in rapor \u015fart\u0131 getirilmi\u015f ve rapor d\u00fczenleyebilen hekimlere geriatri uzman hekimi eklenmi\u015ftir. &nbsp; \u0130\u00e7 referans fiyatland\u0131rma ve e\u015fde\u011fer band\u0131 uygulamas\u0131 27.11.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girmi\u015f olup, di\u011fer de\u011fi\u015fiklikler 03.12.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir. https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf<\/p>\n","protected":false},"author":4,"featured_media":191,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_canvas","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oda"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"og:description\" content=\"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 B\u0130LG\u0130 NOTU &nbsp; \u201c4.2.1.C-Biyolojik ajanlar\u201d ba\u015fl\u0131kl\u0131 maddesine; \u201c(5) Tan\u0131 de\u011fi\u015fikli\u011finin olu\u015fmas\u0131 halinde yeni tan\u0131da idame kriterleri ge\u00e7erlidir.\u201d f\u0131kras\u0131 eklenmi\u015ftir. &nbsp; \u201c4.2.1.C-5 -Tosilizumab\u201d etkin maddesiyle (ACTEMRA) ilgili olarak Dev h\u00fccreli arteriti tan\u0131s\u0131nda; &nbsp; -\u201cY\u00fcksek doz kortikosteroidle birlikte Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131ndan onayl\u0131 olmas\u0131 halinde methotreksat, leflunomid, azatioprinin herhangi birinin 3 ay s\u00fcre ile kullan\u0131lm\u0131\u015f olmas\u0131na ra\u011fmen yan\u0131t al\u0131namamas\u0131 durumunda.\u201d maddesi eklenmi\u015ftir. &nbsp; -Rapor ve re\u00e7ete d\u00fczenleyebilen hekimler aras\u0131ndan, \u201cAlerji uzman hekimleri\u201d \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. &nbsp; 4.2.1.C-6 maddesinde, upadasitinib etkin maddesinin (RINVOQ) \u201cUpadasitinibin Dev H\u00fccreli Arteriti (DHA) hastal\u0131\u011f\u0131nda\u201d kullan\u0131m\u0131nda geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; 4.2.1.C-9- Sekukinumab (VERXANT) maddesinde, \u201cAktif orta il\u0103 \u015fiddetli hidradenitis s\u00fcp\u00fcratival\u0131 (akne inversa) eri\u015fkin hastalarda\u201d kullan\u0131m\u0131na y\u00f6nelik geri \u00f6deme ko\u015fullar\u0131 belirlenmi\u015ftir. &nbsp; \u201cvortioksetin\u201d etkin maddeli ila\u00e7lar (FONKSERA, SORDENA); \u201cyaln\u0131zca orta veya a\u011f\u0131r depresif bozukluk tedavisinde\u201d kar\u015f\u0131lan\u0131rken, yap\u0131lan de\u011fi\u015fiklik ile geri \u00f6deme ko\u015fulu \u201cmajor depresif epizotlar\u0131n tedavisinde\u201d \u015feklinde d\u00fczenlenmi\u015ftir. &nbsp; 4.2.2 maddesinden \u201cBrekspiprazol etkin maddeli ila\u00e7lar (REXULTI) maj\u00f6r depresif bozukluk (MDD) endikasyonunda \u00f6denmez.\u201d \u0130fadesi kald\u0131r\u0131lm\u0131\u015ft\u0131r. &nbsp; DMAH\u2019lar\u0131n raporsuz olarak re\u00e7ete edilme ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, ba\u015flang\u0131\u00e7 rapor s\u00fcresi 3 aydan 6 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. 1 y\u0131l rapor s\u00fcreli devam tedavisi ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, 1 y\u0131ldan uzun s\u00fcreli kullan\u0131ma ili\u015fkin olan d\u00fczenleme 6 aya indirilmi\u015ftir. Gebelikte geri \u00f6denme ko\u015fuluna ili\u015fkin rapor s\u00fcresi 9 aydan 10 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. Raporsuz acil ve yatan hastalarda t\u00fcm hekimlerce re\u00e7ete edilmesi halinde \u00f6denmeye devam edecektir. &nbsp; Abirateron etkin maddesinin (ABIRATEX) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; \u0130ksazomib(NINLARO), karfilzomib(KYPROLIS), daratumumab(DARZALEX), isatuksimab(SARCLISA), elranatamab(ELREXFIO), selineksor(NEXPOVIO) ve pomalidomid(IMNOVID) etken maddeli ila\u00e7lar\u0131n \u00f6zel h\u00fck\u00fcmleri d\u0131\u015f\u0131nda birbirleri ile kombine olarak kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Daratumumab direnci olan hastalarda isatuksimab\u0131n, isatuksimab direnci olan hastalarda daratumumab\u0131n kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u201cisatuksimab\u201d, \u201celranatamab\u201d, \u201cselineksor\u201d ve \u201cfedratinib\u201d(INREBIC) etkin maddelerinin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u0130ki ya\u015f\u0131na kadar inek s\u00fct\u00fc ve\/veya \u00e7oklu g\u0131da protein alerjisi olan bebeklerde kullan\u0131lan t\u0131bbi mamalar i\u00e7in rapor d\u00fczenleyebilecek hekimlere \u00e7ocuk alerji uzman hekimleri eklenmi\u015ftir. &nbsp; Dan\u0131\u015ftay 10. Dairesinin 30.10.2024 tarih ve 2023\/4913 esas say\u0131l\u0131 karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; Mepolizumab(NUCALA) ve benralizumab(FASENRA) etkin maddelerinin ast\u0131m tan\u0131s\u0131nda kullan\u0131lmas\u0131na ili\u015fkin rapor ve re\u00e7ete d\u00fczenleyebilecek hekimler aras\u0131na alerji uzman hekimleri eklenmi\u015ftir. &nbsp; \u201cKombine koag\u00fclasyon fakt\u00f6r\u00fc\/protrombinkompleksi konsantreleri\u201d geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Bosentan etkin maddesini 32 mg dozunda i\u00e7eren ila\u00e7lar\u0131n pulmoner arteriyel hipertansiyonda ve Dijital \u00fclseri olan sistemik skleroz hastalar\u0131nda kullan\u0131m\u0131na ili\u015fkin geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Empagliflozin ve linagliptin etkin maddelerini kombine \u015fekilde i\u00e7eren ila\u00e7lar\u0131n (GLYXAMBI) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015f olup; Linagliptin ve empagliflozin kombinasyonunun, di\u011fer DPP-4 antagonistleri, SGLT2 inhibit\u00f6rleri ve GLP-1 analoglar\u0131 ile birlikte kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 belirtilmi\u015ftir. \u0130\u00e7 referans fiyatland\u0131rma uygulamas\u0131ndaki, grubun en ucuz ila\u00e7 bedelinin %10 fazlas\u0131na kadar\u0131 dikkate al\u0131nmas\u0131 hususundaki oran, %6 olarak g\u00fcncellenmi\u015ftir. &nbsp; Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar listesine \u0130satuksimab ve Sekukinumab etkin maddeleri eklenmi\u015ftir. &nbsp; Siklopiroks olamin \u015fampuan formlar\u0131 (LOPROX \u015eAMPUAN) i\u00e7in Ek-4\/E\u2019de yer alan re\u00e7ete edilme ko\u015fulu, aile hekimlerinin de re\u00e7ete edebilece\u011fi \u015fekilde d\u00fczenlenmi\u015ftir. &nbsp; EK-4\/F Listesinde Paliperidonun 6 ayl\u0131k depo parenteral formlar\u0131 i\u00e7in geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; 28.02.2022 tarihli Dan\u0131\u015ftay Karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; EK-4\/F Listesinde solifenasin, tolterodine-L, trospiyum, darifenasin, propiverin, fesoterodin, mirabegron, transdermal oksibutinin ile duloksetin etkin maddeleri i\u00e7in rapor \u015fart\u0131 getirilmi\u015f ve rapor d\u00fczenleyebilen hekimlere geriatri uzman hekimi eklenmi\u015ftir. &nbsp; \u0130\u00e7 referans fiyatland\u0131rma ve e\u015fde\u011fer band\u0131 uygulamas\u0131 27.11.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girmi\u015f olup, di\u011fer de\u011fi\u015fiklikler 03.12.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir. https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/\" \/>\n<meta property=\"og:site_name\" content=\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T14:41:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T08:12:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Yeni Admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Yeni Admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/\"},\"author\":{\"name\":\"Yeni Admin\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\"},\"headline\":\"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.\",\"datePublished\":\"2025-12-02T14:41:00+00:00\",\"dateModified\":\"2026-01-19T08:12:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/\"},\"wordCount\":754,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"articleSection\":[\"ODA\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/\",\"name\":\"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"datePublished\":\"2025-12-02T14:41:00+00:00\",\"dateModified\":\"2026-01-19T08:12:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/urfaeo-logo2.png\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/2025\\\/12\\\/02\\\/25-kasim-2025-tarihli-sut-degisikligi-hk\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Anasayfa\",\"item\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#website\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#organization\",\"name\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"contentUrl\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/22022021211638-19929-73208.png\",\"width\":635,\"height\":635,\"caption\":\"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131\"},\"image\":{\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/#\\\/schema\\\/person\\\/f482a8288e46359eb9acced6151e1120\",\"name\":\"Yeni Admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g\",\"caption\":\"Yeni Admin\"},\"url\":\"https:\\\/\\\/sanliurfaeo.birodam.org.tr\\\/index.php\\\/author\\\/yeniadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/","og_locale":"tr_TR","og_type":"article","og_title":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","og_description":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 B\u0130LG\u0130 NOTU &nbsp; \u201c4.2.1.C-Biyolojik ajanlar\u201d ba\u015fl\u0131kl\u0131 maddesine; \u201c(5) Tan\u0131 de\u011fi\u015fikli\u011finin olu\u015fmas\u0131 halinde yeni tan\u0131da idame kriterleri ge\u00e7erlidir.\u201d f\u0131kras\u0131 eklenmi\u015ftir. &nbsp; \u201c4.2.1.C-5 -Tosilizumab\u201d etkin maddesiyle (ACTEMRA) ilgili olarak Dev h\u00fccreli arteriti tan\u0131s\u0131nda; &nbsp; -\u201cY\u00fcksek doz kortikosteroidle birlikte Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131ndan onayl\u0131 olmas\u0131 halinde methotreksat, leflunomid, azatioprinin herhangi birinin 3 ay s\u00fcre ile kullan\u0131lm\u0131\u015f olmas\u0131na ra\u011fmen yan\u0131t al\u0131namamas\u0131 durumunda.\u201d maddesi eklenmi\u015ftir. &nbsp; -Rapor ve re\u00e7ete d\u00fczenleyebilen hekimler aras\u0131ndan, \u201cAlerji uzman hekimleri\u201d \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. &nbsp; 4.2.1.C-6 maddesinde, upadasitinib etkin maddesinin (RINVOQ) \u201cUpadasitinibin Dev H\u00fccreli Arteriti (DHA) hastal\u0131\u011f\u0131nda\u201d kullan\u0131m\u0131nda geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; 4.2.1.C-9- Sekukinumab (VERXANT) maddesinde, \u201cAktif orta il\u0103 \u015fiddetli hidradenitis s\u00fcp\u00fcratival\u0131 (akne inversa) eri\u015fkin hastalarda\u201d kullan\u0131m\u0131na y\u00f6nelik geri \u00f6deme ko\u015fullar\u0131 belirlenmi\u015ftir. &nbsp; \u201cvortioksetin\u201d etkin maddeli ila\u00e7lar (FONKSERA, SORDENA); \u201cyaln\u0131zca orta veya a\u011f\u0131r depresif bozukluk tedavisinde\u201d kar\u015f\u0131lan\u0131rken, yap\u0131lan de\u011fi\u015fiklik ile geri \u00f6deme ko\u015fulu \u201cmajor depresif epizotlar\u0131n tedavisinde\u201d \u015feklinde d\u00fczenlenmi\u015ftir. &nbsp; 4.2.2 maddesinden \u201cBrekspiprazol etkin maddeli ila\u00e7lar (REXULTI) maj\u00f6r depresif bozukluk (MDD) endikasyonunda \u00f6denmez.\u201d \u0130fadesi kald\u0131r\u0131lm\u0131\u015ft\u0131r. &nbsp; DMAH\u2019lar\u0131n raporsuz olarak re\u00e7ete edilme ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, ba\u015flang\u0131\u00e7 rapor s\u00fcresi 3 aydan 6 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. 1 y\u0131l rapor s\u00fcreli devam tedavisi ko\u015fulu kald\u0131r\u0131lm\u0131\u015f olup, 1 y\u0131ldan uzun s\u00fcreli kullan\u0131ma ili\u015fkin olan d\u00fczenleme 6 aya indirilmi\u015ftir. Gebelikte geri \u00f6denme ko\u015fuluna ili\u015fkin rapor s\u00fcresi 9 aydan 10 aya \u00e7\u0131kar\u0131lm\u0131\u015ft\u0131r. Raporsuz acil ve yatan hastalarda t\u00fcm hekimlerce re\u00e7ete edilmesi halinde \u00f6denmeye devam edecektir. &nbsp; Abirateron etkin maddesinin (ABIRATEX) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; \u0130ksazomib(NINLARO), karfilzomib(KYPROLIS), daratumumab(DARZALEX), isatuksimab(SARCLISA), elranatamab(ELREXFIO), selineksor(NEXPOVIO) ve pomalidomid(IMNOVID) etken maddeli ila\u00e7lar\u0131n \u00f6zel h\u00fck\u00fcmleri d\u0131\u015f\u0131nda birbirleri ile kombine olarak kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Daratumumab direnci olan hastalarda isatuksimab\u0131n, isatuksimab direnci olan hastalarda daratumumab\u0131n kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u201cisatuksimab\u201d, \u201celranatamab\u201d, \u201cselineksor\u201d ve \u201cfedratinib\u201d(INREBIC) etkin maddelerinin geri \u00f6denme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; \u0130ki ya\u015f\u0131na kadar inek s\u00fct\u00fc ve\/veya \u00e7oklu g\u0131da protein alerjisi olan bebeklerde kullan\u0131lan t\u0131bbi mamalar i\u00e7in rapor d\u00fczenleyebilecek hekimlere \u00e7ocuk alerji uzman hekimleri eklenmi\u015ftir. &nbsp; Dan\u0131\u015ftay 10. Dairesinin 30.10.2024 tarih ve 2023\/4913 esas say\u0131l\u0131 karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; Mepolizumab(NUCALA) ve benralizumab(FASENRA) etkin maddelerinin ast\u0131m tan\u0131s\u0131nda kullan\u0131lmas\u0131na ili\u015fkin rapor ve re\u00e7ete d\u00fczenleyebilecek hekimler aras\u0131na alerji uzman hekimleri eklenmi\u015ftir. &nbsp; \u201cKombine koag\u00fclasyon fakt\u00f6r\u00fc\/protrombinkompleksi konsantreleri\u201d geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Bosentan etkin maddesini 32 mg dozunda i\u00e7eren ila\u00e7lar\u0131n pulmoner arteriyel hipertansiyonda ve Dijital \u00fclseri olan sistemik skleroz hastalar\u0131nda kullan\u0131m\u0131na ili\u015fkin geri \u00f6deme ko\u015fullar\u0131 d\u00fczenlenmi\u015ftir. &nbsp; Empagliflozin ve linagliptin etkin maddelerini kombine \u015fekilde i\u00e7eren ila\u00e7lar\u0131n (GLYXAMBI) geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015f olup; Linagliptin ve empagliflozin kombinasyonunun, di\u011fer DPP-4 antagonistleri, SGLT2 inhibit\u00f6rleri ve GLP-1 analoglar\u0131 ile birlikte kullan\u0131lmas\u0131 halinde bedelleri Kurumca kar\u015f\u0131lanmayaca\u011f\u0131 belirtilmi\u015ftir. \u0130\u00e7 referans fiyatland\u0131rma uygulamas\u0131ndaki, grubun en ucuz ila\u00e7 bedelinin %10 fazlas\u0131na kadar\u0131 dikkate al\u0131nmas\u0131 hususundaki oran, %6 olarak g\u00fcncellenmi\u015ftir. &nbsp; Kat\u0131l\u0131m Pay\u0131ndan Muaf \u0130la\u00e7lar listesine \u0130satuksimab ve Sekukinumab etkin maddeleri eklenmi\u015ftir. &nbsp; Siklopiroks olamin \u015fampuan formlar\u0131 (LOPROX \u015eAMPUAN) i\u00e7in Ek-4\/E\u2019de yer alan re\u00e7ete edilme ko\u015fulu, aile hekimlerinin de re\u00e7ete edebilece\u011fi \u015fekilde d\u00fczenlenmi\u015ftir. &nbsp; EK-4\/F Listesinde Paliperidonun 6 ayl\u0131k depo parenteral formlar\u0131 i\u00e7in geri \u00f6deme ko\u015fulu d\u00fczenlenmi\u015ftir. &nbsp; 28.02.2022 tarihli Dan\u0131\u015ftay Karar\u0131 ile y\u00fcr\u00fct\u00fcm\u00fc durdurulan madde yeniden d\u00fczenlenerek; EK-4\/F Listesinde solifenasin, tolterodine-L, trospiyum, darifenasin, propiverin, fesoterodin, mirabegron, transdermal oksibutinin ile duloksetin etkin maddeleri i\u00e7in rapor \u015fart\u0131 getirilmi\u015f ve rapor d\u00fczenleyebilen hekimlere geriatri uzman hekimi eklenmi\u015ftir. &nbsp; \u0130\u00e7 referans fiyatland\u0131rma ve e\u015fde\u011fer band\u0131 uygulamas\u0131 27.11.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girmi\u015f olup, di\u011fer de\u011fi\u015fiklikler 03.12.2025 tarihinde y\u00fcr\u00fcrl\u00fc\u011fe girecektir. https:\/\/www.resmigazete.gov.tr\/eskiler\/2025\/11\/20251125-7.pdf","og_url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/","og_site_name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","article_published_time":"2025-12-02T14:41:00+00:00","article_modified_time":"2026-01-19T08:12:32+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","type":"image\/png"}],"author":"Yeni Admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Yeni Admin","Tahmini okuma s\u00fcresi":"4 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#article","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/"},"author":{"name":"Yeni Admin","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120"},"headline":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK.","datePublished":"2025-12-02T14:41:00+00:00","dateModified":"2026-01-19T08:12:32+00:00","mainEntityOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/"},"wordCount":754,"commentCount":0,"publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","articleSection":["ODA"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/","name":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK. - \u015eanl\u0131urfa Eczac\u0131 Odas\u0131","isPartOf":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#primaryimage"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#primaryimage"},"thumbnailUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","datePublished":"2025-12-02T14:41:00+00:00","dateModified":"2026-01-19T08:12:32+00:00","breadcrumb":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#primaryimage","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/urfaeo-logo2.png","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/2025\/12\/02\/25-kasim-2025-tarihli-sut-degisikligi-hk\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Anasayfa","item":"https:\/\/sanliurfaeo.birodam.org.tr\/"},{"@type":"ListItem","position":2,"name":"25 KASIM 2025 TAR\u0130HL\u0130 SUT DE\u011e\u0130\u015e\u0130KL\u0130\u011e\u0130 HK."}]},{"@type":"WebSite","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#website","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","description":"","publisher":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sanliurfaeo.birodam.org.tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Organization","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#organization","name":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131","url":"https:\/\/sanliurfaeo.birodam.org.tr\/","logo":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/","url":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","contentUrl":"https:\/\/sanliurfaeo.birodam.org.tr\/wp-content\/uploads\/2025\/09\/22022021211638-19929-73208.png","width":635,"height":635,"caption":"\u015eanl\u0131urfa Eczac\u0131 Odas\u0131"},"image":{"@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/sanliurfaeo.birodam.org.tr\/#\/schema\/person\/f482a8288e46359eb9acced6151e1120","name":"Yeni Admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b1bcfc5d55af4e7fc9737f956325e8d9203056464179614b915004d0d1be29d3?s=96&d=mm&r=g","caption":"Yeni Admin"},"url":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/author\/yeniadmin\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/5426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/comments?post=5426"}],"version-history":[{"count":0,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/posts\/5426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media\/191"}],"wp:attachment":[{"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/media?parent=5426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/categories?post=5426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sanliurfaeo.birodam.org.tr\/index.php\/wp-json\/wp\/v2\/tags?post=5426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}